BioNTech and OncoC4 reported Phase 3 data showing their anti‑CTLA‑4 antibody improved overall survival in lung cancer, with the initial headline-grabbing efficacy tempered by a tougher tolerability profile on closer review. Company press releases highlighted a clinically meaningful mortality reduction; independent analysis flagged higher rates of immune-related adverse events compared with some existing regimens. Analysts and clinicians noted the survival result is significant for a checkpoint-class agent, but tolerability will shape patient selection and commercial uptake. The dataset and safety details were discussed in regulatory filings and analyst notes following the topline announcement.